Thursday, October 20, 2011

Medtronic tests stent for erectile dysfunction

(Reuters) -

Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.

The medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED), each of whom had a stent -- a tiny wire mesh tube similar to those used to prop open heart arteries -- which was placed in the internal pudendal artery, which supplies blood to the penis.. After three months the results were promising, the company said.

Researcher Dr. Jason Rogers said up to 50 percent of men discontinue drug therapy -- which includes Viagra, Levitra and Cialis -- either because it did not work or because they could not tolerate side effects, including lowering of blood pressure.

Rogers noted that there were no adverse events reported by participants in the trial up to three months later, but heacknowledged that risks may become evident much later and stressed that the stenting procedure is still investigational and requires more research.


Read More:

Medtronic tests stent for erectile dysfunction



Wednesday, October 19, 2011

Male breast cancer rare, but can be aggressive

NEW YORK (Reuters Health) -

Men get diagnosed with breast cancer at less than one percent the rate of women, according to a new analysis of cancer rates from six cities and countries.

But when they did get breast cancer, men were caught with more advanced disease, on average, and were more likely to die from it.

Men are most commonly in their 60s or 70s when diagnosed with breast cancer, according to the National Cancer Institute. Radiation exposure and diseases that increase estrogen levels - such as liver cirrhosis or Klinefelter syndrome, a genetic disorder - are among factors that raise a man's risk.

The United States Preventive Services Task Force, a federally-supported panel that sets guidelines for cancer screening, does not recommend regular breast cancer screening in men without symptoms.

Read the full report:
Male breast cancer rare, but can be aggressive


Friday, October 14, 2011

Infections after prostate biopsy on the rise

NEW YORK (Reuters Health) -

Serious infections after prostate biopsies appear to be on the rise in the U.S., possibly fueled by antibiotic-resistant bacteria, a new study of elderly men suggests.

More than a million prostate biopsies are done each year on Medicare patients, often to investigate suspicious results from prostate cancer screening. But the majority of those are false alarms, and some doctors worry that many men could be suffering needlessly due to screening.

Just last week, a government-funded expert panel concluded that prostate cancer screening saves few or no lives, but causes harm through treatment or further invasive testing such as biopsies.

Read more:
Infections after prostate biopsy on the rise


Friday, October 7, 2011

FDA OKs Impotence Drug Cialis to Treat Enlarged Prostate (HealthDay)


THURSDAY, Oct. 6 (HealthDay News) --

The U.S. Food and Drug Administration announced late Thursday that it had approved using the erectile dysfunction drug Cialis as a treatment for enlarged prostate.

The FDA said its approval was made on the basis of three studies. Two of the studies looked at changes in BPH symptom severity based on the International Prostate Symptom Score. Those trials found that men who took the 5-milligram dose of Cialis one per day experienced an improvement in BPH symptoms vs. men who took a dummy pill.

The FDA warned that Cialis, which is made by Eli Lilly and Co., "should not be used in patients taking nitrates, for example nitroglycerin, because the combination can cause an unsafe decrease in blood pressure." People taking heart medications known as alpha blockers should also avoid Cialis because its use alongside these drugs has not yet been studied and the combination might lower blood pressure.

Read More:
FDA OKs Impotence Drug Cialis to Treat Enlarged Prostate

Groups defend need for prostate screening

CHICAGO (Reuters) -

Reports that an influential group of advisers plans to recommend against routine screening of prostate cancer has drawn criticism from health groups worried the move will increase cancer deaths in men - despite much research which has shown the total uselessness of PSA testing.

The New York Times on Thursday reported that the U.S. Preventive Services Task Force is thinking of recommending against use of the prostate-specific antigen or PSA test.

The task force, an independent panel appointed by the federal government, plans to give a common blood test known as the PSA test a rating of "D," suggesting there is moderate or high certainty that the test has no net benefit or that the harms outweigh the benefits.

Current recommendations say there is insufficient evidence to support the use of the test.


Read more here:

Groups defend need for prostate screening


Friday, September 30, 2011

Otherwise Healthy Older Men Undertreated for Prostate Cancer: Study (HealthDay)

THURSDAY, Sept. 29 (HealthDay News) --

Men over 75 with prostate cancer who are otherwise healthy are being undertreated for their condition, according to a new study.

Full Story:

Otherwise Healthy Older Men Undertreated for Prostate Cancer

Wednesday, September 28, 2011

Urinary Symptoms Not Helped by Saw Palmetto

Saw palmetto doesn't ease urinary symptoms

NEW YORK (Reuters Health) -

A new study concludes that saw palmetto, a plant extract sold as a natural boost to urinary health, actually doesn't improve symptoms of enlarged prostate in middle-aged men.

While saw palmetto's usefulness has been in doubt for a while, Bent added, the new research "very definitively" shows that it doesn't ease the urinary trouble caused by an enlarged prostate.

Dr. Michael Barry of Massachusetts General Hospital in Boston said that the findings don't mean that nobody should take the plant extract -- even if its only benefit may come from men believing it will help.
"It appears there were essentially no side effects, and that some men improved," he said. "I wouldn't object to men giving it a try to see how it worked for them."